Open AccessDaily practice use of bortezomib in relapsed/refractory multiple myeloma: Safety/efficacy results of a compassionate use program in Switzerland
Author(s) -
Helene Freimann,
Antonello Calderoni,
P Cornu,
Robert A. Olie
Publication year - 2007
Publication title -
swiss medical weekly
Language(s) - English
Resource type - Journals
eISSN - 1424-7860
pISSN - 1424-3997
DOI - 10.4414/smw.2007.11716
Subject(s) - medicine , bortezomib , multiple myeloma , refractory (planetary science) , adverse effect , clinical trial , oncology , surgery , physics , astrobiology
Several publications reported on the safety and efficacy of bortezomib, a novel first-in-class anti-cancer agent, in the treatment of relapsed/refractory multiple myeloma in controlled clinical trials. Complementary data on the experience with bortezomib in daily oncology practice are needed. We report on the use of bortezomib to treat patients with relapsed/refractory multiple myeloma in routine clinical practice.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom